Veterinärmedizinische Universität Wien Forschungsinformationssystem VetDoc

Grafischer Link zur Startseite der Vetmeduni Vienna

Age-Related Changes in Hematopoiesis

Abstract
ARCH is a network of highly qualified experts in experimental hematology created to decipher the causal relationship between the physiological changes in the hematopoietic system during lifespan and the parallel occurrence of specific age- related hematological diseases (pediatric, adult, elderly), with the aim to develop novel targeted therapeutic treatments. ARCH research will integrate the results from complementary model systems (cell lines, mouse models, cells from leukemia patients) and it will deploy a large panel of cutting-edge technologies, such as single cells genomics, epigenomics, genome editing and organoid cultures, in a multi-faceted effort. The ARCH ambitious goal requires scientific and financial resources beyond the capability of a single group. To reach this goal, the ARCH network brings together 15 beneficiaries (12 academic, 2 SMEs and 1 private research institute) and 4 Partner organisations (2 academic, 1 SME and 1 patients’ association). Two European Consortia are present through their italian nodes. ARCH will recruit 15 ESRs that will be all enrolled in PhD programmes. Besides research laboratory work, the ARCH training programme includes scientific, technical and transferable skills courses that will provide ESRs with a solid scientific culture and with awareness of responsible research and innovation issues. This broad portfolio will enable ESRs to become leading academic, clinic or industrial players in the field. The unique combination of scientific excellence, quality of the educational programme and experience in translating basic research into exploitable results will provide ARCH with the real possibility of positively contributing to the enhancement of European competitiveness in the development of innovative, targeted drugs/treatments for hematological diseases, which currently represent a serious socio-economical problem for the European health care system.
Kurzbezeichnung
ARCH
Koordination an der Vetmeduni Vienna
Grebien Florian
Koordination Gesamtprojekt
Università degli Studi di Milano-Bicocca, Piazza dell'Ateneo Nuovo, 20126 Mailand, Italien
Laufzeit
01.06.19-31.12.23
Programm
Horizon 2020 - Excellent Science - Marie S. Curie (MSCA) - Innovative Training Networks (ITN) H2020
Art der Forschung
Grundlagenforschung
Mitarbeiter/innen
Grebien F.,
Beteiligte Vetmed-Organisationseinheiten
Institut für Medizinische Biochemie
(Weitere) Projektpartner
Academisch Ziekenhuis Groningen, Hanzeplein 1, 9713 GZ Groningen, Niederlande
Agencia Estatal Consejo superior de Investigaciones Cientificas, Madrid, Spanien
Centre Europeen de Recherche en Biologie et Medecine , 1 rue Laurent Fries, 67404 Illkirch, Frankreich
Diagenode s.a., Rue Bois Saint-Jean, 3, 4102 Seraing (Ougrée), Belgien
FlowMetric Europe, S.p.A., Via Ludovico Ariosto 21, 20091 Bresso, Italien
Fondazione Tettamenti Onlus, Via Giambattista Pergolesi, 33, 20900 Monza, Italien
IDRYMA IATROVIOLOGIKON EREUNON AKADEMIAS ATHINON, SORANOU EFESIOU 4, 115 27 Athen, Griechenland
Institut Curie, 26 rue d'Ulm / 73 rue Claude Bernard (HQ), 75248 Paris cedex 05, Frankreich
Institut National de la Sante et de la Recherche Medicale (INSERM), 101 rue de Tolbiac, 75654 Paris, Frankreich
King´s College London, De Crespigny Park, GB London, Großbritannien
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., Hofgartenstraße 8, 80539 München, Deutschland
Tel Aviv University, Israel
Universita degli studi di roma la sapienza, Italien
Gefördert durch
EU (Kommission der Europäischen Union), Rue de la Loi, Brussels, Europäische Union
Publikation

Heyes, E; Schmidt, L; Manhart, G; Eder, T; Proietti, L; Grebien, F (2021): Identification of gene targets of mutant C/EBPα reveals a critical role for MSI2 in CEBPA-mutated AML. Leukemia. 2021 35 (9) 2526-2538.

© Veterinärmedizinische Universität Wien Hilfe und DownloadsErklärung zur Barrierefreiheit